MNMD vs. MOR, TWST, VCEL, CPRX, MLTX, MRUS, BEAM, IBRX, ARWR, and HCM
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), Catalyst Pharmaceuticals (CPRX), MoonLake Immunotherapeutics (MLTX), Merus (MRUS), Beam Therapeutics (BEAM), ImmunityBio (IBRX), Arrowhead Pharmaceuticals (ARWR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.
Mind Medicine (MindMed) vs.
MorphoSys (NASDAQ:MOR) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
Mind Medicine (MindMed) has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.
Mind Medicine (MindMed) has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Mind Medicine (MindMed)'s return on equity of -47.56% beat MorphoSys' return on equity.
MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500.
MorphoSys presently has a consensus price target of $18.25, suggesting a potential downside of 3.74%. Mind Medicine (MindMed) has a consensus price target of $26.33, suggesting a potential upside of 223.94%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher probable upside, analysts plainly believe Mind Medicine (MindMed) is more favorable than MorphoSys.
18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 2.3% of Mind Medicine (MindMed) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Mind Medicine (MindMed) had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Mind Medicine (MindMed) and 0 mentions for MorphoSys. Mind Medicine (MindMed)'s average media sentiment score of 0.63 beat MorphoSys' score of 0.00 indicating that Mind Medicine (MindMed) is being referred to more favorably in the news media.
Mind Medicine (MindMed) received 28 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 92.98% of users gave Mind Medicine (MindMed) an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
Summary
Mind Medicine (MindMed) beats MorphoSys on 16 of the 18 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
This page (NASDAQ:MNMD) was last updated on 2/21/2025 by MarketBeat.com Staff
Free MNMD Stock Alerts